about
Tumor immunotargeting using innovative radionuclidesA pretargeting system for tumor PET imaging and radioimmunotherapyComparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals.Antitumor immunity induced after α irradiationSyndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumorsCombining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.Cancer radioimmunotherapy with alpha-emitting nuclides.Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical ModelImprovement of the Targeting of Radiolabeled and Functionalized Liposomes with a Two-Step System Using a Bispecific Monoclonal Antibody (Anti-CEA × Anti-DTPA-In).Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsTherapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal CarcinomatosisImmuno-PET for Clinical Theranostic Approaches.Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO--a selected review.Radiolabeled antibodies for cancer imaging and therapy.Radioimmunoconjugates for the treatment of cancer.Radioimmunoconjugates for treating cancer: recent advances and current opportunities.Radioimmunotherapy for Treatment of Acute Leukemia.Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide.Unprecedented incorporation of α-emitter radioisotope 213Bi into porphyrin chelates with reference to a daughter isotope mediated assistance mechanism.The intraportal injection model for liver metastasis: advantages of associated bioluminescence to assess tumor growth and influences on tumor uptake of radiolabeled anti-carcinoembryonic antigen antibody.Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
P50
Q28083230-6D712B68-BC21-4FC8-85B8-14F111CBCFF9Q28087820-03385BB9-C0D4-450B-A64E-4B15A48CEA93Q33388981-83109E97-8D1C-42EE-A392-05EF8FFB71EAQ33400076-48443253-EC16-4BB2-B547-714F515EFE33Q33788353-78ACC920-A33C-4C16-95DB-EEEFFD4F7950Q33891246-F085FA60-91AC-4AC5-87A2-1DDA4E6C5837Q35650530-745354E0-C4F8-483D-9DB3-015B81536796Q35670632-9F1627B1-BEE0-46BF-A55C-C3228CCB81B4Q36102652-3858BE8A-5F9A-47DD-91D2-134BC1594D37Q36245624-95C33758-D7E8-4B91-9F03-05D2F82BD288Q36316395-C6A196FF-BFBC-4BB8-9EF6-243EA720ACA2Q36323585-2C36425F-459E-4C61-8C7C-ACB7AD33F806Q36387694-67A73364-EA7D-49E9-96BC-24EA1C8007D0Q37631461-A4360FE5-B68A-4E0C-97A1-F6345DCFF2DEQ37973297-456E0A1D-DC7C-449A-9515-736B10695407Q38036119-A8F1E9DC-03F2-4300-A760-16C25AE4EE3AQ38273846-D8417041-14B8-404F-8946-CA237FA69FE2Q38691472-6A79C71B-7015-4050-A7C3-5FCD31F424B9Q38742247-EF374499-0DFF-421F-A236-E807E2C65487Q39486574-7CA995C9-41D4-4E0D-A081-1614CDD83235Q39516860-43B40AC7-9500-418E-A56D-A7CE1CA035EAQ39626139-065E475E-A8D9-4867-9C81-366537FF5B1FQ39744448-ACDC10B5-6AC1-49A8-B880-62878B668DBB
P50
description
onderzoeker
@nl
name
Alain Faivre-Chauvet
@ast
Alain Faivre-Chauvet
@en
Alain Faivre-Chauvet
@es
type
label
Alain Faivre-Chauvet
@ast
Alain Faivre-Chauvet
@en
Alain Faivre-Chauvet
@es
prefLabel
Alain Faivre-Chauvet
@ast
Alain Faivre-Chauvet
@en
Alain Faivre-Chauvet
@es
P214
P244
P268
P2732
P106
P21
P213
0000 0000 8372 6640
P214
P244
P268
P2732
P31
P569
1933-01-01T00:00:00Z
P570
1997-01-01T00:00:00Z
P735
P7859
lccn-n79033587